What are the recommended antibiotic regimens for adult patients with infections caused by Enterococcus faecalis and Enterococcus faecium, including dosing and duration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Enterococcus faecalis and Enterococcus faecium Infections

For susceptible E. faecalis infections, use ampicillin 2 g IV every 4 hours plus gentamicin 3 mg/kg/day for 4-6 weeks, or ampicillin 2 g IV every 4 hours plus ceftriaxone 2 g IV every 12 hours for 6 weeks. 1, 2

E. faecalis: Susceptible Strains

First-Line Regimens (Beta-lactam and Aminoglycoside Susceptible)

Standard combination therapy:

  • Ampicillin 2 g IV every 4 hours (or amoxicillin 200 mg/kg/day in 4-6 divided doses) PLUS gentamicin 3 mg/kg/day IV/IM 2
    • Duration: 4-6 weeks for native valve endocarditis (4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months or prosthetic valve) 1
    • Gentamicin duration: Some experts recommend only 2 weeks of gentamicin to reduce nephrotoxicity, though full 4-6 week courses remain acceptable 2
    • Monitor gentamicin levels: peak 3-4 μg/mL, trough <1 μg/mL 1

Alternative for aminoglycoside-resistant strains (high-level resistance):

  • Ampicillin 2 g IV every 4 hours PLUS ceftriaxone 2 g IV every 12 hours for 6 weeks 1, 2
    • This double beta-lactam regimen is the preferred choice for high-level aminoglycoside-resistant (HLAR) E. faecalis 2
    • Critical caveat: This combination is NOT active against E. faecium 2
    • Lower nephrotoxicity risk compared to aminoglycoside-containing regimens 1
    • Can be modified for outpatient therapy: ceftriaxone 4 g once daily plus ampicillin 2 g every 4 hours via programmable pump 3

Beta-Lactam Intolerant Patients

If unable to tolerate ampicillin/penicillin:

  • Vancomycin 30 mg/kg/day IV in 2 divided doses PLUS gentamicin 3 mg/kg/day for 6 weeks 1
    • Target vancomycin trough: 10-20 μg/mL (some sources recommend ≥20 mg/L) 2, 1
    • Less effective than beta-lactam combinations; use only when beta-lactams contraindicated 1

For beta-lactamase-producing E. faecalis (rare):

  • Ampicillin-sulbactam 3 g IV every 6 hours plus gentamicin 1

E. faecium: Intrinsically Resistant Strains

E. faecium commonly exhibits intrinsic penicillin resistance (up to 95% of strains may be multidrug-resistant) 1. The ampicillin-ceftriaxone combination does NOT work for E. faecium 2.

Vancomycin-Susceptible E. faecium

  • Vancomycin 30 mg/kg/day IV in 2 divided doses PLUS gentamicin 3 mg/kg/day for 6 weeks 2

Vancomycin-Resistant Enterococci (VRE)

Most E. faecium strains (95%) are multidrug-resistant; only 3% of E. faecalis are multidrug-resistant 1. Many vancomycin-resistant E. faecalis remain ampicillin-susceptible 1, 4.

For VRE infections:

  1. Linezolid 600 mg IV/PO every 12 hours 1, 5

    • Duration: ≥8 weeks for endocarditis; site-dependent for other infections 2, 5
    • Monitor for hematological toxicity (thrombocytopenia, anemia) 2, 5
    • Effective for both E. faecalis and E. faecium 1

  2. High-dose daptomycin 8-12 mg/kg/day IV 5

    • Consider combination with beta-lactams (ampicillin, ceftaroline, or ertapenem) for enhanced activity 2, 5
    • Some experts add fosfomycin 2 g IV every 6 hours to prevent daptomycin resistance 2
    • Monitor CPK levels weekly 2
    • For E. faecalis with daptomycin MIC 4 mg/L (intermediate): high-dose daptomycin ≥8 mg/kg shows similar efficacy to alternatives 6

  3. Alternative agents:

    • Tigecycline 100 mg IV loading, then 50 mg IV every 12 hours - for intra-abdominal VRE infections 5
    • Quinupristin-dalfopristin 7.5 mg/kg IV every 8 hours - active ONLY against E. faecium, NOT E. faecalis; rarely used due to severe myalgias 1

  4. For uncomplicated VRE urinary tract infections:

    • Fosfomycin 3 g PO single dose 5
    • Nitrofurantoin 100 mg PO every 6 hours 5
    • High-dose ampicillin 18-30 g IV daily (if ampicillin-susceptible VRE E. faecalis) 5, 4

Critical Considerations

Aminoglycoside Dosing and Monitoring

  • Use divided doses (every 8 hours) rather than once-daily dosing for enterococcal infections - conflicting data on once-daily efficacy 1
  • Avoid streptomycin if creatinine clearance <50 mL/min 1
  • Monitor renal function and drug levels weekly (twice weekly if renal impairment) 2
  • Older, debilitated patients with enterococcal infections are at high risk for aminoglycoside nephrotoxicity 1

Duration of Therapy

  • Native valve endocarditis: 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months 1
  • Prosthetic valve endocarditis: Minimum 6 weeks 1, 2
  • Double beta-lactam regimen: Always 6 weeks regardless of symptom duration 1
  • VRE endocarditis: ≥8 weeks 2

Resistance Testing Requirements

  • Mandatory susceptibility testing: Test for beta-lactam, aminoglycoside (including high-level resistance), vancomycin, daptomycin, and linezolid susceptibility 1
  • High-level gentamicin resistance (MIC >500 mg/L): If streptomycin-susceptible, substitute streptomycin 15 mg/kg/day in 2 divided doses 2

Common Pitfalls

  • Do NOT use ampicillin-ceftriaxone for E. faecium - it lacks activity 2
  • Do NOT use quinupristin-dalfopristin for E. faecalis - it is inactive 1
  • Do NOT use cephalosporins or carbapenems as monotherapy - enterococci have intrinsic resistance 7
  • Vancomycin-gentamicin is less effective than ampicillin-gentamicin; reserve for true beta-lactam allergy 1
  • 82% of VRE E. faecalis remain ampicillin-susceptible - consider ampicillin before broad-spectrum agents 4

Multidisciplinary Management

All patients with multidrug-resistant enterococcal infections require consultation with infectious diseases, cardiology, cardiovascular surgery, and clinical pharmacy specialists 1.

References

Related Questions

In a young patient hospitalized with infective endocarditis and Janeway lesions who is currently receiving ceftriaxone, what are the next management steps and considerations?
Is a penicillin‑sensitive Enterococcus faecalis susceptible to oxacillin?
What empiric antimicrobial therapy should be started for an adult patient with aerobic cultures showing moderate growth Enterococcus faecalis and heavy growth of Gram‑negative bacilli?
Can I use ceftriaxone in a patient with a mild ampicillin allergy for culture‑negative infective endocarditis, and what is the recommended treatment duration for native versus prosthetic valves?
In an elderly patient with recent Enterococcus faecalis urinary tract infection, bacteremia, and endocarditis, a 4 mm aortic bioprosthetic valve opacity, now presenting with painful palpable purpura that has progressed to bullae and new transaminitis while on daptomycin, who previously received intravenous ampicillin and ceftriaxone (Rocephin) and has a history of transcatheter aortic valve replacement (TAVR) with pacemaker, atrial fibrillation on apixaban (Eliquis), and daily furosemide with as‑needed potassium supplementation, how should I work up and manage the suspected drug‑induced bullous leukocytoclastic vasculitis versus other vasculitic etiologies from a pharmacy standpoint?
What is the appropriate dose of 200 mg/40 mg Bactrim (trimethoprim‑sulfamethoxazole) for a child weighing 21.6 kg?
What are the differences among the available methylphenidate formulations (immediate‑release, sustained‑release, extended‑release, and transdermal) regarding onset of action, duration of effect, dosing schedule, and clinical use?
What initial fibrate dose should be started for a patient with triglycerides of 715 mg/dL, normal renal function (creatinine clearance > 30 mL/min), and no contraindications?
How should I describe diffuse hazy attenuation on chest CT consistent with vascular congestion and lacking subpleural sparing?
Should a pregnancy test be obtained before starting testosterone therapy in a patient assigned female at birth who could be pregnant?
How should I manage sleep, anxiety, and depression in a patient with prolonged grief disorder who has failed multiple antidepressants, discontinued medications for depression, post‑traumatic stress disorder, and anxiety, and has a heart murmur and atrial fibrillation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.